Abstract 1768
Background
Taste changes can frequently be observed in oncological patients undergoing chemotherapy and are reported as being among the most distressing side effects, along with fatigue, nausea, vomiting, and hair loss. The prevalence of taste changes have been reported in the range of 46%–77%. The aim of this descriptive study was to evaluate taste changes experienced by cancer patients who receive chemotherapy and associated factors with taste changes.
Methods
This is a descriptive a study. The sample of the study consisted of 154 patients who received chemotherapy at Gayrettepe Florence Nightingale Hospital during the period of February 2018 to July 2018. Data were collected by using the patient İnformation form and Chemotherapy-induced Taste Alteration Scale (CiTAS). Mann-Whitney U test, Kruskal-Wallis test, and Spearman Correlation analysis were used to evaluate the data.
Results
The mean age of patients was 57,40±12,748 years, 62.3% of them were women, 43.5% of them were university graduates, 73.4% were married and 70.8% of them were employed in any job. According to CiTAS scores, the most discomfort in taste patients experienced was because of nausea, vomiting, odor disturbance and loss of appetite during the chemotherapy process. According to CiTAS score the least discomfort experienced by patients were tasting basic flavors including the taste of the sweet, salty, bitter flavors and the broth. As a result of the comparison of CiTAS score some sociodemographic and medical characteristics of patients, it was found that women experience more paraguzi and fantoguzi than men. As the age of the patients increased, the problems in taste were decreased. Patients who do not take other drugs than chemotherapy have fewer taste problems.
Conclusions
In conclusion, it is recommended to include changes in taste sensation along with other side effects in the evaluation of treatment-related processes of cancer patients, and to add practices related to management of taste changes in the care plan of the patients by taking into account the factors that may be associated with taste.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4600 - Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Presenter: Lucio Ghiglione
Session: Poster Display session 3
Resources:
Abstract
3547 - Real World Outcomes of Immune-Related Adverse Events (irAEs) among Patients Receiving Immune Checkpoint Inhibitors (ICIs) in Hospital Settings
Presenter: Saby George
Session: Poster Display session 3
Resources:
Abstract
1124 - Sex-based heterogeneity of efficacy of anticancer immunotherapy
Presenter: Fabio Conforti
Session: Poster Display session 3
Resources:
Abstract
4133 - Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis
Presenter: Qingyuan Huang
Session: Poster Display session 3
Resources:
Abstract
2548 - Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients
Presenter: Jacobo Rogado
Session: Poster Display session 3
Resources:
Abstract
2228 - Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma
Presenter: Antoine Italiano
Session: Poster Display session 3
Resources:
Abstract
2333 - Efficacy and safety of immune checkpoint inhibitors (ICIs) for treatment of advanced solid tumours in octogenarian patients
Presenter: Soraya Mebarki
Session: Poster Display session 3
Resources:
Abstract
4847 - Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies
Presenter: Aracelis Torres
Session: Poster Display session 3
Resources:
Abstract
2215 - Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting
Presenter: Pauline Corbaux
Session: Poster Display session 3
Resources:
Abstract
2881 - Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Joaquin Mosquera Martinez
Session: Poster Display session 3
Resources:
Abstract